Company intelligence / Profile preview

Cyclogenix

Aberdeen (outskirts), Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

Cyclogenix is an early-stage UK biotech developing a cyclotide-based macrocyclic peptide and antibody discovery platform; public information indicates platform and discovery work rather than any disclosed clinical-stage programs.[1][2][3][4]

Modalities: PeptidesBicyclic peptidesProteinBiologic
Industry: Biotech

Partnerships

Wyeth (historical peptide technology collaboration via University of Queensland cyclotide platform)[5]

Beyond the preview

Go deeper on Cyclogenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclogenix.

Explore the full profile